AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
On June 17, 2025, Regeneron's trading volume reached $391 million, a 44.15% decrease from the previous day, ranking 195th in the day's stock market activity. Regeneron's stock price fell by 2.65%, marking the second consecutive day of decline, with a total decrease of 3.85% over the past two days.
Regeneron Pharmaceuticals has withdrawn from the bidding war for 23andMe, shifting its focus to genetic research projects. This move allows TTAM Research Institute, a nonprofit controlled by Anne Wojcicki, to proceed with its $305 million bid for 23andMe.
had initially offered $256 million for the company, but decided not to increase its offer, opting instead to invest in genetics and data-driven health through its existing platforms.Wojcicki's proposal to regain control of 23andMe offers better reassurances to customers and aims to continue the company's original mission. The strategic pivot by Regeneron enables Anne Wojcicki’s TTAM Research Institute to potentially take control of 23andMe with a $305 million proposition. This decision underscores a growing focus on innovation and specialization in the biotech sector, as Regeneron aims to establish itself as a leader in precision medicine.
Hunt down the stocks with explosive trading volume.

Dec.05 2025

Dec.05 2025

Dec.05 2025

Dec.05 2025

Dec.05 2025
Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet